Novartis CAR-T chief drops out of Big Pharma, joins the great migration to a favorite biotech destination
Novartis may still have big plans for CAR-T, but the pharma giant continues to bleed top talent from the group.
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
